Trelegy Ellipta 200mcg

Description

Trelegy Ellipta 200 mcg
(Fluticasone Furoate 200 mcg / Umeclidinium 62.5 mcg / Vilanterol 25 mcg)

Description:
Trelegy Ellipta 200 mcg is a once-daily, fixed-dose combination inhaler used for the long-term maintenance treatment of chronic obstructive pulmonary disease (COPD) in adults. This triple combination medication contains fluticasone furoate (200 mcg), a corticosteroid that reduces airway inflammation; umeclidinium (62.5 mcg), a long-acting muscarinic antagonist (LAMA) that helps relax airway muscles; and vilanterol (25 mcg), a long-acting beta-agonist (LABA) that helps to open the airways. Together, these three ingredients provide comprehensive 24-hour control over COPD symptoms, improving lung function, reducing exacerbations, and helping patients breathe easier.

Trelegy Ellipta 200 mcg is specifically designed for the long-term management of COPD, offering patients the convenience of a once-daily inhaler. It is not intended for the relief of acute symptoms or sudden flare-ups of COPD. This inhaler simplifies treatment by combining three classes of medications in a single device, providing effective symptom control with minimal effort.

Key Features:

• Triple Combination Therapy: Contains fluticasone furoate (200 mcg), a potent anti-inflammatory corticosteroid, umeclidinium (62.5 mcg), a LAMA that improves airflow by relaxing airway muscles, and vilanterol (25 mcg), a LABA that further helps to open the airways for better breathing.
• Once-Daily Dosing: A single inhalation per day delivers 24-hour relief, helping to control COPD symptoms and improve overall lung function.
• Effective COPD Management: Combines three different classes of medication to target key aspects of COPD: inflammation, bronchoconstriction, and airflow restriction.
• Ellipta Inhaler Technology: The Ellipta inhaler is pre-loaded and easy to use, providing accurate, reliable doses of medication. It is designed for simplicity, requiring minimal steps to administer.